Related Experiment Video
Updated: Aug 15, 2026
Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models
Published on: February 3, 2026
A review of systemic therapy for advanced pancreatic cancer
Basil F El-Rayes1, Philip A Philip
1Division of Hematology and Oncology, Karmanos Cancer Institute, Wayne State University, 4100 John R. Street, Detroit, MI 48201, USA. philipp@karmanos.org
Abstract:
Pancreatic cancer remains an important cause of cancer mortality with few long-term survivors. Improvement in the systemic therapy of pancreatic cancer is necessary to treat the frequently encountered metastatic disease. Several new chemotherapeutic agents with modest activity against pancreatic cancer have been identified over the past decade. Gemcitabine is currently the standard treatment for advanced pancreatic cancer. Combination chemotherapy trials incorporating gemcitabine, cisplatin, 5-fluorouracil, oxaliplatin, or irinotecan generally show improved outcomes in objective response rates but with little or no improvement in survival in phase III trials. Novel therapeutic strategies targeting dysregulated molecular pathways in pancreatic cancer cells are currently being explored. Future treatment regimens for pancreatic cancer will probably incorporate conventional cytotoxic drugs and novel targeted agents.
Insights
Pancreatic cancer treatment requires improved systemic therapies for metastatic disease. While combination chemotherapy shows modest response rates, future regimens will likely combine cytotoxic drugs with novel targeted agents for better outcomes.
Area of Science:
- Oncology
- Medical Research
Background:
- Pancreatic cancer is a leading cause of cancer mortality with limited long-term survival.
- Effective systemic therapy for metastatic pancreatic cancer is urgently needed.
- Current treatments offer modest benefits, necessitating novel therapeutic approaches.
Purpose of the Study:
- To review the current state of systemic therapy for advanced pancreatic cancer.
- To evaluate the efficacy of existing chemotherapeutic agents and combination regimens.
- To explore emerging targeted therapies for pancreatic cancer.
Main Methods:
- Review of recent clinical trials and literature on pancreatic cancer systemic therapy.
- Analysis of response rates and survival data from combination chemotherapy trials.
- Discussion of novel molecular pathways and targeted agents under investigation.
Main Results:
- Gemcitabine is the current standard for advanced pancreatic cancer.
- Combination chemotherapy (gemcitabine, cisplatin, 5-fluorouracil, oxaliplatin, irinotecan) improves objective response rates but not survival.
- Novel targeted therapies are being explored to address treatment limitations.
Conclusions:
- Systemic therapy for pancreatic cancer requires significant improvement.
- Future treatment strategies will likely integrate conventional chemotherapy with targeted agents.
- Further research into molecular pathways is crucial for developing more effective pancreatic cancer treatments.
Related Concept Videos
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...